
ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FORECAST 2019-2027
Asia Pacific Active Pharmaceutical Ingredients Market by Types (Generic Apis, Innovative Apis) by Manufacturers (Captive Apis, Merchant Apis) by Synthesis (Biotech, Synthetic) by Application (Cardiovascular Disease, Oncology, Cns and Neurological Disorders, Orthopedic Disorders, Endocrinology, Pulmonology, Gastrointestinal Disorders, Nephrology, Ophthalmology, Other Application) by Geography.
Several chemical substances are contained within the drugs and the portion that metabolizes in treating the condition at the location of interest, i.e., the active part is known as ‘Active Pharmaceutical Ingredients’ or API in short. While each drug also consists of an excipient part, called the carrier, it is the API that is considered while prescribing a drug.
The Asia Pacific active pharmaceutical ingredients market is escalating at a significant growth rate of 6.10% CAGR during the forecasting years of 2019-2027. The availability of cheap labor in this densely populated region coupled with the establishment of market players in the developing countries in APAC is expected to drive the market growth.
The economies of China, India, Japan, South Korea, Australia and the remaining countries collectively forming the Rest of Asia Pacific regional segment are the major revenue contributors to the APAC active pharmaceutical ingredients market. The healthcare expenditure in China is projected to reach a huge value soon because the nation shelters the largest population in the world, where there has been a significant rise in chronic conditions such as that of cancer, cardiovascular diseases, diabetes, and obesity, etc. These factors together drive the API market development.
Japan makes up another significantly large market in the Asia Pacific region for the API market. The high rise in geriatric population in the country coupled with higher expectation for an enhanced quality of life will be driving the market demand in the country.
The increasing prevalence of cancer and other chronic diseases is giving rise to a huge target population in the APAC regional market. Also, the major markets in this region, including China and India, are developing in terms of technology. Availability of cheap labor and lenient regulatory framework are attracting foreign companies to set up manufacturing facilities in this region. This is the most important key factor for the increasing growth potential in this region for the key manufacturers.
The major market players operating in the APAC region, which are exhaustively profiled in terms of their adopted market strategies, business segments are Merck & Co., Inc., Aurobindo Pharma, Albemarle Corporation, Dr. Reddy’s Laboratories, Teva Pharmaceutical Industries, Ltd., Bayer AG, Cipla, Eli Lilly and Company, Lonza Group AG, Boehringer Ingelheim GmbH, Abbvie, Inc., Novartis, Mylan N.V., Bristol-Myers Squibb, and Sun Pharmaceuticals Industries, Ltd.
To request a free sample copy of this report, please complete the form below:
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.
- RESEARCH SCOPE
- STUDY GOALS
- SCOPE OF THE MARKET STUDY
- WHO WILL FIND THIS REPORT USEFUL?
- STUDY AND FORECASTING YEARS
- RESEARCH METHODOLOGY
- SOURCES OF DATA
- SECONDARY DATA
- PRIMARY DATA
- TOP-DOWN APPROACH
- BOTTOM-UP APPROACH
- DATA TRIANGULATION
- SOURCES OF DATA
- EXECUTIVE SUMMARY
- MARKET SUMMARY
- KEY FINDINGS
- INNOVATIVE APIS HOLDS THE LARGEST MARKET SHARE IN TERMS OF ACTIVE PHARMACEUTICAL INGREDIENTS TYPE
- MERCHANT APIS ARE THE FASTEST GROWING MANUFACTURERS
- BIOTECH IS THE FASTEST GROWING SYNTHESIS SEGMENT
- ONCOLOGY IS THE MAJORLY USED APPLICATION
- MARKET DYNAMICS
- MARKET SCOPE & DEFINITION
- MARKET DRIVERS
- GROWING GERIATRIC POPULATION
- GROWING PREVALENCE OF INFECTIOUS DISEASES AND HOSPITAL ACQUIRED INFECTIONS
- INCREASING INCIDENCE OF AGE-RELATED DISEASES
- MARKET RESTRAINTS
- HIGH COST OF INVESTMENT AND PRODUCTION COST
- AGGRESSIVE COMPETITION AMONG API MANUFACTURERS
- MARKET OPPORTUNITIES
- GAINING POPULARITY FOR TARGETED THERAPY
- GROWING PREFERENCE FOR OUTSOURCING APIS
- IMPLEMENTING MEASURES AGAINST COUNTERFEIT DRUGS
- MARKET CHALLENGES
- STRINGENT GOVERNMENT REGULATIONS
- AVAILABILITY OF COUNTERFEIT PRODUCTS
- MARKET BY TYPES
- GENERIC APIS
- INNOVATIVE APIS
- MARKET BY MANUFACTURERS
- CAPTIVE APIS
- MERCHANT APIS
- MARKET BY SYNTHESIS
- BIOTECH
- MONOCLONAL ANTIBODIES
- RECOMBINANT PROTEINS
- VACCINES
- SYNTHETIC
- BIOTECH
- MARKET BY APPLICATION
- CARDIOVASCULAR DISEASE
- ONCOLOGY
- CNS AND NEUROLOGICAL DISORDERS
- ORTHOPEDIC DISORDERS
- ENDOCRINOLOGY
- PULMONOLOGY
- GASTROINTESTINAL DISORDERS
- NEPHROLOGY
- OPHTHALMOLOGY
- OTHER APPLICATION
- KEY ANALYTICS
- PORTER’S FIVE FORCES MODEL
- THREAT OF NEW ENTRANTS
- THREAT OF SUBSTITUTE
- BARGAINING POWER OF BUYERS
- BARGAINING POWER OF SUPPLIERS
- THREAT OF COMPETITIVE RIVALRY
- PESTEL ANALYSIS
- SUPPLY CHAIN ANALYSIS
- OPPORTUNITY MATRIX
- PORTER’S FIVE FORCES MODEL
- GEOGRAPHICAL ANALYSIS
- ASIA PACIFIC
- JAPAN
- CHINA
- INDIA
- AUSTRALIA
- SOUTH KOREA
- REST OF ASIA PACIFIC
- ASIA PACIFIC
- COMPETITIVE LANDSCAPE
- MARKET POSITION ANALYSIS
- COMPANY PROFILES
- ABBVIE, INC.
- ALBEMARLE CORPORATION
- AUROBINDO PHARMA
- BAYER AG
- BOEHRINGER INGELHEIM GMBH
- BRISTOL-MYERS SQUIBB
- CIPLA
- REDDY’S LABORATORIES
- ELI LILLY AND COMPANY
- LONZA GROUP AG
- MERCK & CO., INC.
- MYLAN N.V.
- NOVARTIS
- SUN PHARMACEUTICALS INDUSTRIES, LTD.
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
TABLE LIST
TABLE 1Â Â Â Â Â Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
TABLE 2Â Â Â Â Â Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPES 2019-2027 ($ MILLION)
TABLE 3Â Â Â Â Â Â Â ASIA PACIFIC GENERIC APIS MARKET 2019-2027 ($ MILLION)
TABLE 4Â Â Â Â Â Â Â ASIA PACIFIC INNOVATIVE APIS MARKET 2019-2027 ($ MILLION)
TABLE 5Â Â Â Â Â Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURERS 2019-2027 ($ MILLION)
TABLE 6Â Â Â Â Â Â Â ASIA PACIFIC CAPTIVE APIS MARKET 2019-2027 ($ MILLION)
TABLE 7Â Â Â Â Â Â Â ASIA PACIFIC MERCHANT APIS MARKET 2019-2027 ($ MILLION)
TABLE 8Â Â Â Â Â Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY SYNTHESIS 2019-2027 ($ MILLION)
TABLE 9Â Â Â Â Â Â Â ASIA PACIFIC BIOTECH MARKET 2019-2027 ($ MILLION)
TABLE 10Â Â Â Â Â ASIA PACIFIC BIOTECH MARKET BY TYPES 2019-2027 ($ MILLION)
TABLE 11Â Â Â Â Â ASIA PACIFIC MONOCLONAL ANTIBODIES MARKET 2019-2027 ($ MILLION)
TABLE 12Â Â Â Â Â ASIA PACIFIC RECOMBINANT PROTEINS MARKET 2019-2027 ($ MILLION)
TABLE 13Â Â Â Â Â ASIA PACIFIC VACCINES MARKET 2019-2027 ($ MILLION)
TABLE 14Â Â Â Â Â ASIA PACIFIC SYNTHETIC MARKET 2019-2027 ($ MILLION)
TABLE 15Â Â Â Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY APPLICATION 2019-2027 ($ MILLION)
TABLE 16Â Â Â Â Â ASIA PACIFIC CARDIOVASCULAR DISEASE MARKET 2019-2027 ($ MILLION)
TABLE 17Â Â Â Â Â ASIA PACIFIC ONCOLOGY MARKET 2019-2027 ($ MILLION)
TABLE 18Â Â Â Â Â ASIA PACIFIC CNS AND NEUROLOGICAL DISORDERS MARKET 2019-2027 ($ MILLION)
TABLE 19Â Â Â Â Â ASIA PACIFIC ORTHOPEDIC DISORDERS MARKET 2019-2027 ($ MILLION)
TABLE 20Â Â Â Â Â ASIA PACIFIC ENDOCRINOLOGY MARKET 2019-2027 ($ MILLION)
TABLE 21Â Â Â Â Â ASIA PACIFIC PULMONOLOGY MARKET 2019-2027 ($ MILLION)
TABLE 22Â Â Â Â Â ASIA PACIFIC GASTROINTESTINAL DISORDERS MARKET 2019-2027 ($ MILLION)
TABLE 23Â Â Â Â Â ASIA PACIFIC NEPHROLOGY MARKET 2019-2027 ($ MILLION)
TABLE 24Â Â Â Â Â ASIA PACIFIC OPHTHALMOLOGY MARKET 2019-2027 ($ MILLION)
TABLE 25Â Â Â Â Â ASIA PACIFIC OTHER APPLICATION MARKET 2019-2027 ($ MILLION)
TABLE 26Â Â Â Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
TABLE 27Â Â Â Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 28Â Â Â Â Â ACTIVE PHARMACEUTICAL INGREDIENTS COMPANY MARKET POSITION ANALYSIS 2017
FIGURE LIST
FIGURE 1Â Â Â Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
FIGURE 2Â Â Â Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY TYPES 2018 & 2027 (%)
FIGURE 3Â Â Â Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GENERIC APIS 2019-2027 ($ MILLION)
FIGURE 4Â Â Â Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY INNOVATIVE APIS 2019-2027 ($ MILLION)
FIGURE 5Â Â Â Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY MANUFACTURERS 2018 & 2027 (%)
FIGURE 6Â Â Â Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY CAPTIVE APIS 2019-2027 ($ MILLION)
FIGURE 7Â Â Â Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MERCHANT APIS 2019-2027 ($ MILLION)
FIGURE 8Â Â Â Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY SYNTHESIS 2017 & 2027 (%)
FIGURE 9Â Â Â Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BIOTECH 2019-2027 ($ MILLION)
FIGURE 10Â Â ASIA PACIFIC BIOTECH MARKET BY MONOCLONAL ANTIBODIES 2019-2027 ($ MILLION)
FIGURE 11Â Â ASIA PACIFIC BIOTECH MARKET BY RECOMBINANT PROTEINS 2019-2027 ($ MILLION)
FIGURE 12Â Â ASIA PACIFIC BIOTECH MARKET BY VACCINES 2019-2027 ($ MILLION)
FIGURE 13Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY SYNTHETIC 2019-2027 ($ MILLION)
FIGURE 14Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY APPLICATION 2018 & 2027 (%)
FIGURE 15Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY CARDIOVASCULAR DISEASE 2019-2027 ($ MILLION)
FIGURE 16Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY ONCOLOGY 2019-2027 ($ MILLION)
FIGURE 17Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY CNS AND NEUROLOGICAL DISORDERS 2019-2027 ($ MILLION)
FIGURE 18Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY ORTHOPEDIC DISORDERS 2019-2027 ($ MILLION)
FIGURE 19Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY ENDOCRINOLOGY 2019-2027 ($ MILLION)
FIGURE 20Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY PULMONOLOGY 2019-2027 ($ MILLION)
FIGURE 21Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GASTROINTESTINAL DISORDERS 2019-2027 ($ MILLION)
FIGURE 22Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY NEPHROLOGY 2019-2027 ($ MILLION)
FIGURE 23Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY OPHTHALMOLOGY 2019-2027 ($ MILLION)
FIGURE 24Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY OTHER APPLICATION 2019-2027 ($ MILLION)
FIGURE 25  PORTER’S FIVE FORCE MODEL
FIGURE 26Â Â ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET REGIONAL OUTLOOK 2018 & 2027 (%)
FIGURE 27Â Â JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
FIGURE 28Â Â CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
FIGURE 29Â Â INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
FIGURE 30Â Â AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
FIGURE 31Â Â SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
FIGURE 32Â Â REST OF ASIA PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
- GEOGRAPHICAL ANALYSIS
- ASIA PACIFIC
- JAPAN
- CHINA
- INDIA
- AUSTRALIA
- SOUTH KOREA
- REST OF ASIA PACIFIC
- ASIA PACIFIC
- MARKET BY TYPES
- GENERIC APIS
- INNOVATIVE APIS
- MARKET BY MANUFACTURERS
- CAPTIVE APIS
- MERCHANT APIS
- MARKET BY SYNTHESIS
- BIOTECH
- MONOCLONAL ANTIBODIES
- RECOMBINANT PROTEINS
- VACCINES
- SYNTHETIC
- BIOTECH
- MARKET BY APPLICATION
- CARDIOVASCULAR DISEASE
- ONCOLOGY
- CNS AND NEUROLOGICAL DISORDERS
- ORTHOPEDIC DISORDERS
- ENDOCRINOLOGY
- PULMONOLOGY
- GASTROINTESTINAL DISORDERS
- NEPHROLOGY
- OPHTHALMOLOGY
- OTHER APPLICATION
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.